OncoImmunology最新收录文章列表-丁香通

简称ONCOIMMUNOLOGY

新锐分类医学

JCR分类免疫学、肿瘤学

ISSN2162-402X

EISSN2162-402X

出版商TAYLOR & FRANCIS INC

新锐分区2 区

2025 JIF6.2

JIF分区Q1

简介

《OncoImmunology》是Taylor & Francis出版的肿瘤免疫学,创刊于2012年,是肿瘤免疫学领域具有影响力的开放获取期刊。期刊位列JCR Q1区和中科院1区,涵盖肿瘤免疫治疗、肿瘤微环境免疫等学科,主要刊载肿瘤免疫学领域的研究论文。

最新文献

A targeted MAVS fusion protein for controlled innate immune activation and antitumor therapy.

PMID: 400855082025-12

Differential impact of genetic deletion of TIGIT or PD-1 on melanoma-specific T-lymphocytes.

PMID: 389835992024-07-08

Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity.

PMID: 389489312024-06-27

Near-infrared duocarmycin photorelease from a Treg-targeted antibody-drug conjugate improves efficacy of PD-1 blockade in syngeneic murine tumor models.

PMID: 389157822024-06

Lymphatic endothelial cell-mediated accumulation of CD177+Treg cells suppresses antitumor immunity in human esophageal squamous cell carcinoma.

PMID: 385162692024-03

Lactate/GPR81 recruits regulatory T cells by modulating CX3CL1 to promote immune resistance in a highly glycolytic gastric cancer.

PMID: 384197592024-02-26

LFA-1 regulated by IL-2/STAT5 pathway boosts antitumor function of intratumoral CD8+ T cells for improving anti-PD-1 antibody therapy.

PMID: 381257212023-12-14

Tumor-intrinsic RGS1 potentiates checkpoint blockade response via ATF3-IFNGR1 axis.

PMID: 382643432023-11

TNBC-derived Gal3BP/Gal3 complex induces immunosuppression through CD45 receptor.

PMID: 375936772023-08-14

Daratumumab诱导原发性渗出性淋巴瘤的细胞介导细胞毒性并对难治性疾病有效

PMID: 366325652023-01-07

Overcoming the resistance of hepatocellular carcinoma to PD-1/PD-L1 inhibitor and the resultant immunosuppression by CD38 siRNA-loaded extracellular vesicles.

PMID: 366056192022-12-26

Oncolytic adenovirus promotes vascular normalization and nonclassical tertiary lymphoid structure formation through STING-mediated DC activation.

PMID: 358001552022-07-01

Glucose metabolism inhibitor PFK-015 combined with immune checkpoint inhibitor is an effective treatment regimen in cancer.

PMID: 357072212022-05-25

TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy.

PMID: 356464752022-05-24

Carbon ion radiotherapy triggers immunogenic cell death and sensitizes melanoma to anti-PD-1 therapy in mice.

PMID: 353556802022-03-25

MerTK-mediated efferocytosis promotes immune tolerance and tumor progression in osteosarcoma through enhancing M2 polarization and PD-L1 expression.

PMID: 350360762022-01-12

Landscape of cancer-associated fibroblasts identifies the secreted biglycan as a protumor and immunosuppressive factor in triple-negative breast cancer.

PMID: 350038992022-01-03

卡瑞利珠单抗联合多西他赛、顺铂和放疗治疗局部晚期食管鳞状细胞癌：一项1b期研究

PMID: 346165882021-09-28

Fn14-targeted BiTE and CAR-T cells demonstrate potent preclinical activity against glioblastoma.

PMID: 345950612021-09-27

Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse.

PMID: 332246292020-11-09